Viromed Medical AG receives high six-figure funding from German Federal Ministry for cold plasma technology development, including PulmoPlas® for respiratory infectionsViromed Medical AG receives high six-figure funding from German Federal Ministry for cold plasma technology development, including PulmoPlas® for respiratory infections

Viromed Medical AG Secures Federal Funding for Cold Plasma Medical Device Development

2026/03/24 05:08
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Viromed Medical AG has received funding approval from Germany’s Federal Ministry of Research, Technology and Space for research and development projects in cold plasma technology. The certification was granted under the Research Allowance Act (FZulG) and comprises funding in the high six-figure euro range, marking a substantial investment in medical innovation.

The funding focuses on developing innovative medical systems for cold atmospheric plasma application, including a stationary system for integration into ventilation processes called PulmoPlas®. This technology aims to selectively inactivate pathogenic germs in the lower respiratory tract, potentially enabling new therapeutic approaches in intensive care medicine. Additionally, the development of a mobile device for contact-free plasma application to support wound healing, known as ViroCap®, is being funded through this initiative.

Both projects address key medical challenges and expand the current state of the art in medical technology. The application of cold plasma in the lungs represents a particularly novel approach for which no comparable systems currently exist, according to the company. This funding underscores Viromed’s innovative capabilities and confirms the scientific and technological relevance of its solutions in the medical field.

With this financial support, Viromed is advancing the development of both PulmoPlas® and ViroCap® systems, strengthening its position in non-pharmacological treatment of infectious diseases. The company, which has been listed on the stock exchange since October 2022, focuses on distributing innovative cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. More information about the company can be found at https://www.viromed-medical-ag.de.

The funding represents a significant step toward realizing the growth potential of cold plasma technology in medicine. By developing these specialized systems, Viromed aims to provide healthcare professionals with new tools to combat infections and improve patient outcomes through advanced technological solutions that operate without traditional pharmaceuticals.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Viromed Medical AG Secures Federal Funding for Cold Plasma Medical Device Development.

The post Viromed Medical AG Secures Federal Funding for Cold Plasma Medical Device Development appeared first on citybuzz.

Market Opportunity
SIX Logo
SIX Price(SIX)
$0.00925
$0.00925$0.00925
+1.09%
USD
SIX (SIX) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

KAIO Global Debut

KAIO Global DebutKAIO Global Debut

Enjoy 0-fee KAIO trading and tap into the RWA boom